Canadian biotech company reports positive autism treatment results

• Marvel Biosciences reported promising interim results from on its lead drug candidate, MB-204, as a new treatment for autism
• The study demonstrated that a single oral dose of MB-204 can restore social interaction behaviours to normal levels, with notable improvements in cognitive function
• The team stated these unexpected findings indicate a substantial potential of MB-204 to address the core symptoms of autism
• Marvel Biosciences Corp. last traded at $0.16 per share

Marvel Biosciences (TSXV:MRVL) reported promising interim results from on its lead drug candidate, MB-204, as a new treatment for autism.

The study, conducted by the iBrain Institute in Tours, France, demonstrated that a single oral dose of MB-204 can restore social interaction behaviours to normal levels in autism model mice, with notable improvements in cognitive function, an advancement that could signify a pivotal shift in autism therapy.

Investigating the effects of MB-204 on socialization and cognition, the study found that MB-204 not only fully restored social deficits at a single oral dose, but also enhanced certain social behaviours beyond normal levels. The team stated these unexpected findings indicate a substantial potential of MB-204 to address the core symptoms of autism.

“We have also seen a single oral dose can have an immediate effect in depression in mice, but to see an immediate effect after one dose in autism is remarkable,” Marvel Biosciences’ CSO, Mark Williams, said in a news release. “We look forward to completing the current study and then testing MB-204 in other models of autism.”

MB-204 was previously being developed by the company to treat Alzheimer’s disease and depression.

Marvel Biosciences Corp., with its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company that utilizes a “drug redevelopment” approach to drug development.

Marvel Biosciences Corp. last traded at $0.16 per share and its stock has risen 52.38 per cent in a year’s time.

Join the discussion: Find out what everybody’s saying about this stock on the Marvel Biosciences Bullboard investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards.

The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.